{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:47:47Z","timestamp":1793249267668,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.molmet.2025.102298","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:01:41Z","timestamp":1765526501000},"page":"102298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies"],"prefix":"10.1016","volume":"103","author":[{"given":"William","family":"Roell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Alsina-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchang","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"Coskun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libbey","family":"O'Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W.","family":"Sloop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Ficorilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Regmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallikarjuna","family":"Rettiganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Urva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmet.2025.102298_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2025.102298_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.molmet.2025.102298_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.molmet.2025.102298_bib4","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2025.102298_bib5","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.molmet.2025.102298_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.molmet.2025.102298_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.molmet.2025.102298_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.molmet.2025.102298_bib9","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"10.1016\/j.molmet.2025.102298_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.molmet.2025.102298_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.molmet.2025.102298_bib12","first-page":"E185","article-title":"Pancreatic alpha- and beta-cell responses to GIP infusion in normal man","volume":"237","author":"Elahi","year":"1979","journal-title":"Am J Physiol"},{"key":"10.1016\/j.molmet.2025.102298_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00253866","article-title":"The effect of glucose-dependent insulinotropic polypeptide infused at physiological concentrations on the release of insulin in man","volume":"22","author":"Sarson","year":"1982","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2025.102298_bib14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2337\/dbi19-0005","article-title":"GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family","volume":"68","author":"Nauck","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2025.102298_bib15","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","article-title":"Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients","volume":"45","author":"Vilsb\u00f8ll","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2025.102298_bib16","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2025.102298_bib17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2025.102298_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Investig"},{"key":"10.1016\/j.molmet.2025.102298_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/EJE-21-0135","article-title":"Effects of endogenous GIP in patients with type 2 diabetes","volume":"185","author":"Stensen","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.molmet.2025.102298_bib20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.molmet.2025.102298_bib21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.molmet.2025.102298_bib22","article-title":"GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.molmet.2025.102298_bib23","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.molmet.2025.102298_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0167-0115(83)90276-8","article-title":"Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat","volume":"7","author":"Beck","year":"1983","journal-title":"Regul Pept"},{"key":"10.1016\/j.molmet.2025.102298_bib25","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.molmet.2025.102298_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metabol"},{"key":"10.1016\/j.molmet.2025.102298_bib27","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.molmet.2025.102298_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.molmet.2025.102298_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.molmet.2025.102298_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.164921","article-title":"Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding","volume":"8","author":"Adriaenssens","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmet.2025.102298_bib31","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","article-title":"Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study","volume":"62","author":"Bergmann","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2025.102298_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.molmet.2025.102298_bib33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.appet.2014.06.025","article-title":"Reproducibility of subjective appetite ratings and ad libitum test meal energy intake in overweight and obese males","volume":"81","author":"Horner","year":"2014","journal-title":"Appetite"},{"key":"10.1016\/j.molmet.2025.102298_bib34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.molmet.2025.102298_bib35","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2025.102298_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/706416","article-title":"Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus","volume":"2015","author":"Jinnouchi","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.molmet.2025.102298_bib37","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.molmet.2025.102298_bib38","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J Clin Investig"},{"issue":"Suppl 1","key":"10.1016\/j.molmet.2025.102298_bib39","article-title":"A long-acting glucose dependent insulinotropic polypeptide receptor agonist improves insulin sensitivity and beta cell function in subjects with type 2 diabetes [abstract]","volume":"67","author":"Heise","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.molmet.2025.102298_bib40","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.molmet.2025.102298_bib41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jdi.12490","article-title":"Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives","volume":"7","author":"Seino","year":"2016","journal-title":"J Diabetes Investig"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825002054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877825002054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:22:09Z","timestamp":1768954929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877825002054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":41,"alternative-id":["S2212877825002054"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102298","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2025.102298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102298"}}